Join our daily newsletter At The Bell to receive exclusive market insights
- Cann Group (CAN) has received a $3.2 million research and development (R&D) tax incentive refund
- The cash follows on from eligible R&D activities in the 2020 financial year
- Cann says the funds will be reinvested into the continued development of its expansion, commercial activities and product portfolio
- On the market this morning, Cann is down 3.76 per cent and trading at 64 cents per share
Cann Group (CAN) has received a $3.2 million research and development (R&D) tax incentive refund.
The refund covers part of the medicinal cannabis stock’s R&D costs for the 2020 financial year, including its strategic partnerships with key research entities.
The Australian Governments R&D tax incentive program provides companies with an offset for eligible R&D activities.
Cann says the funds will be reinvested into the continued development of its expansion, commercial activities and product portfolio.
“The refund that we have received under the R&D tax incentive program is an indicator of the company’s commitment to research in the medicinal cannabis sector,” CEO Peter Crock said.
“We’ve recently conducted a close review of these R&D programs to ensure we are prioritising our investment appropriately and will continue to see meaningful and beneficial outcomes from these activities,” he added.
Earlier this week, Cann invested C$1 million (just over A$1 million) in pharmaceutical company iuvo Therapeutics. Cann now holds around 2 per cent interest in iuvo.
On the market this morning, Cann is down 3.76 per cent and is trading at 64 cents per share at 11.19 am AEDT.
